The FDA has approved Zanvastro (zilganersen) from Ionis Pharmaceuticals — the first disease-modifying therapy ever approved for Alexander disease, an ultra-rare and relentless neurological disorder.
What Alexander disease is
Alexander disease affects roughly one in one to three million people. It is caused by abnormal activity of the GFAP gene, which produces a structural protein found in astrocytes — the star-shaped support cells that maintain the brain’s chemical environment, regulate blood flow and support neurons.
The mechanism is unusual and important to the treatment strategy. Most genetic diseases involve a loss of function — a missing or broken protein. Alexander disease works the other way: the mutated GFAP protein accumulates to toxic levels inside astrocytes, forming characteristic aggregates. It is a disease of too much of a damaged protein, not too little of a working one.
Patients face seizures, muscle weakness, progressive loss of mobility and difficulty swallowing. Until now there was nothing to slow any of it.
Why that mechanism made it druggable
A gain-of-function disease is, paradoxically, easier to address than a loss-of-function one. Replacing a missing protein means delivering a working gene or the protein itself — hard, particularly in the brain. Reducing production of a harmful protein is a more tractable problem, because it can be done at the level of RNA before the protein exists.
Zanvastro is an antisense oligonucleotide: a short synthetic strand designed to bind the RNA transcript of the GFAP gene and reduce how much protein gets made. It attacks the disease at its source rather than managing its consequences.
What the trial showed
In the pivotal trial, Zanvastro significantly stabilised walking speed in patients over age five compared with controls at week 61, with similar promise in children aged two to four. It is approved for both paediatric and adult patients.
Walking speed is a well-chosen endpoint for this disease. It is objective, it is measurable in young children, and it maps directly onto something families care about. In a progressive disorder, stabilising a declining measure is the realistic goal — the therapy is not restoring lost function but slowing its loss.
Getting a drug into the brain
Antisense oligonucleotides do not meaningfully cross the blood-brain barrier, so neurological ASOs are administered directly into cerebrospinal fluid by lumbar puncture, repeated at intervals for as long as treatment continues.
This is a significant practical commitment — recurring procedures under sedation for young children — and it is one reason distribution of the drug through brain tissue matters. For a disease affecting astrocytes throughout the central nervous system, how far the drug spreads from the injection site is a real determinant of effect.
Why this matters for Ionis specifically
Ionis has spent decades building antisense technology, and its most prominent successes reached patients through partners — most notably in spinal muscular atrophy and in ALS. Zanvastro is the company’s first independently launched neurology drug, meaning it retains commercial control rather than licensing away the upside.
That is a strategic shift as much as a scientific one. A platform company that only licenses assets captures a fraction of their value; one that can launch its own becomes something different.
Recordati holds ex-US rights. Ionis plans a US rollout “in the coming weeks,” with insurance-assistance and affordability programmes. Pricing was not disclosed.
The economics of one in a million
The undisclosed price is the open question, and the arithmetic is unavoidable. A condition affecting one in one to three million people means perhaps a few hundred diagnosed patients in the United States. Development costs comparable to any other drug must be recovered across that population, which is why ultra-rare therapies routinely carry annual prices in the hundreds of thousands of dollars.
Affordability programmes exist precisely because the list price will be unpayable by individuals. The practical question for families is not the headline figure but whether insurers cover it and how quickly — and in a progressive disease, delay in access has a cost measured in function that does not come back.
What it represents
Diagnosis is its own obstacle
An approved therapy only helps patients who are identified, and in ultra-rare disease that is far from automatic.
Alexander disease presents differently depending on age of onset — developmental delay and seizures in infants, gait and speech problems in older children and adults — and those features overlap with far more common conditions. Many patients accumulate years of investigation and provisional diagnoses before the right answer is reached, a pattern documented across rare neurological disease generally.
What has improved the odds is imaging and genetics. Characteristic MRI patterns can raise suspicion, and genetic testing can confirm a GFAP mutation definitively. The existence of a treatment tends to accelerate this on its own: clinicians look harder for a diagnosis that now changes management, and testing pathways get built where previously there was little point. For a progressive disease in which the goal is slowing decline, how early a patient is identified is not an administrative detail — it determines how much function there is left to preserve.
Beyond the individual approval, this is a demonstration that antisense technology can reach populations too small to interest large developers. Where a disease has a clear genetic driver and the therapeutic goal is to reduce production of something harmful, the platform is now capable of turning that into an approved medicine — even at one in a million. Regulatory news, not medical advice.